Basetwo AI联合CPI、Labman与Nicoya演示曲妥珠单抗生物反应器自主闭环控制:机器人取样结合数字SPR滴度检测
加拿大-英国合作演示自主生物反应器控制:机器人取样 + 数字 SPR 滴度检测
Basetwo AI与CPI、Labman、Nicoya合作,在生产曲妥珠单抗生物类似药候选物的补料分批生物反应器中演示了完全自主闭环控制。混合模型在每日取样间预测葡萄糖,模型预测控制器自动调整补料,无需光谱探头即维持葡萄糖目标带,细胞活率与滴度优于人工控制。该方法结合无标记抗体滴度定量与机器人取样,为利用现有基础设施实施先进控制提供路径。
图注:Labman 生物反应器自动化实验平台,一排台式玻璃生物反应器与顶部传感器/管路。图源:news-medical.net(Image credit: Labman)
制药 AI 现场观察 | 主体材料:GlobeNewswire(Basetwo AI 新闻稿,2026-11-11)
来源:https://www.globenewswire.com/news-release/2026/11/11/3400756/0/en/canada-uk-collaboration-demonstrates-autonomous-bioreactor-control-for-a-her2-breast-cancer-therapeutic.html
副题(原文):An AI controller autonomously delivered predictive control of a bioreactor, automatically adjusting nutrient feeds to keep glucose, cell viability, and titer within the target range, using existing process instrumentation and robotic sampling.
(AI 控制器对生物反应器自主实施了预测控制,自动调整补料,使葡萄糖、细胞活率与滴度保持在目标范围内,全程使用现有过程仪表与机器人取样。)
Toronto, ON, Nov. 11, 2026 (GLOBE NEWSWIRE) — Basetwo AI, which builds agentic digital twin software for pharmaceutical and chemical manufacturing, successfully demonstrated predictive control of a bioreactor in a flagship initiative in collaboration with CPI, Labman, and Nicoya. The four companies demonstrated fully autonomous closed-loop control in fed-batch bioreactors producing Trastuzumab, a biosimilar candidate for HER2 breast cancer treatment.
加拿大多伦多,2026 年 11 月 11 日(GLOBE NEWSWIRE)——为制药与化工制造开发智能体数字孪生软件的 Basetwo AI,在与 CPI、Labman 和 Nicoya 的合作旗舰项目中成功展示了对生物反应器的预测控制。四家公司在生产曲妥珠单抗(Trastuzumab,HER2 乳腺癌治疗用生物类似药候选物)的补料分批生物反应器中实现了完全自主的闭环控制。
Under closed-loop control, a hybrid model forecasts glucose between daily samples and a model predictive controller makes smaller, more frequent feeds that hold glucose near its target band. The autonomous AI system successfully predicted glucose demand from cellular activity and automatically decided the feed timing and amount without human intervention. Using this approach, glucose levels were maintained at the target band without a spectroscopic probe. The autonomous control was successfully able to improve cellular viability and titer (yield) in comparison to manual control — which produced glucose-limited conditions in the reactor.
在闭环控制下,一个混合模型在两次每日取样之间预测葡萄糖,模型预测控制器(MPC)以更小、更频繁的补料把葡萄糖维持在目标带附近。自主 AI 系统成功根据细胞活性预测葡萄糖需求,并在无人工干预的情况下自动决定补料时机与补料量。采用该方法,无需光谱探头即把葡萄糖维持在目标带内。与产生葡萄糖受限状态的人工控制相比,自主控制成功改善了细胞活率与滴度(产量)。
The result addresses a common challenge in biopharmaceutical manufacturing and development: achieving continuous visibility and control of critical process variables (CPVs) without relying on additional analytical instrumentation or manual intervention. Today, many bioprocessing teams rely on periodic lab measurements to monitor CPVs like glucose, viable cell density and titer, leaving operators without visibility between samples. While spectroscopic process analytical technologies (PAT) such as Raman and NIR can provide more frequent measurements, their adoption can be costly, requiring additional hardware, calibration, and ongoing maintenance.
该结果针对的是生物制药生产与开发中的一个常见难题:在不依赖额外分析仪器或人工干预的前提下,实现对关键工艺变量(CPV)的连续可见与控制。当前许多生物工艺团队依赖周期性实验室检测来监测葡萄糖、活细胞密度和滴度等 CPV,操作人员在各次取样之间缺乏可见性。拉曼、近红外等光谱类过程分析技术(PAT)虽可提供更频繁的测量,但采用成本高,需要额外硬件、校准与持续维护。
This collaboration demonstrates an alternative to manual sampling and costly instrumentation. By combining label-free quantitation of antibody titer and automated robotic sampling with autonomous AI closed-loop control, this approach offers a potential pathway for bioprocess teams to implement advanced control strategies using the infrastructure they already have.
此次合作展示了人工取样与昂贵仪器之外的另一条路径。将抗体滴度的无标记定量与自动机器人取样同自主 AI 闭环控制相结合,该方法为生物工艺团队提供了用现有基础设施实施先进控制策略的可能途径。
“Biopharma manufacturers have invested heavily in bioreactor infrastructure, but critical process decisions still depend on measurements taken hours apart,” said Thouheed Abdul Gaffoor, CEO of Basetwo. “This work with CPI, Labman, and Nicoya demonstrates that we can use the data already coming from a bioreactor to predict what's happening inside it, automatically adjust the process and ultimately produce higher performance outcomes. This approach makes autonomous process control more accessible without requiring manufacturers to install additional spectroscopic instrumentation.”
“生物制药企业已在生物反应器基础设施上投入重金,但关键工艺决策仍依赖相隔数小时的测量,”Basetwo CEO Thouheed Abdul Gaffoor 说,“我们与 CPI、Labman 和 Nicoya 的这项工作表明,可以直接利用生物反应器已经产生的数据来预测罐内正在发生什么、自动调整工艺并最终取得更优性能。该方法让自主过程控制更容易上手,不要求企业加装额外的光谱仪器。”
“The real opportunity here isn't simply automating laboratory activities, but using the data we generate to make better decisions as a bioprocess develops,” said Philip Probert, Director of Biologics, RNA Centre of Excellence and Medicines Manufacturing Innovation Centre at CPI. “By bringing together automated sampling, analytics and AI-driven control, this collaboration has demonstrated how processes can respond to information in real time, reducing reliance on manual intervention. Demonstrating this approach across different bioreactor scales is an important step towards more autonomous bioprocess development. It highlights the potential to accelerate process understanding, make better use of experimental data and ultimately develop more efficient and robust manufacturing processes.”
“这里真正的机会不只是把实验室活动自动化,而是在生物工艺推进过程中用我们产生的数据做出更好的决策,”CPI 生物制品总监(RNA 卓越中心与药品制造创新中心)Philip Probert 说,“通过把自动取样、分析与 AI 驱动的控制结合在一起,此次合作展示了过程如何实时响应信息、减少对人工干预的依赖。在不同生物反应器规模上验证这一方法,是迈向更自主生物工艺开发的重要一步。它凸显了加速工艺理解、更好利用实验数据并最终开发出更高效稳健生产工艺的潜力。”
“This is a really exciting development for Labman,” said Tom Smith, Head of Bioprocess Automation at Labman. “As an engineering company, we've been able to develop a new platform that automates the sample journey from the bioreactor, a process that has traditionally involved a lot of manual work, from sub-sampling and sample preparation through to equipment integration. We're agnostic to the workflow and its requirements, so it's great to be opening up new opportunities to automate this upstream process.”
“对 Labman 来说这是一个令人兴奋的进展,”Labman 生物工艺自动化负责人 Tom Smith 说,“作为一家工程公司,我们开发出了把样品从生物反应器取出后的全旅程自动化的新平台——这一流程传统上涉及大量手工操作,从分样、样品制备到设备对接。我们对工作流及其要求保持中性,因此能为自动化这一上游流程打开新机会,令人高兴。”
“Real-time process control depends on knowing what's actually in the vessel, not just what the sensors around it are reporting,” said Jamie McQuay, VP of Engineering at Nicoya. “Getting that answer has traditionally meant pulling a sample and waiting on the lab. In this platform, Digital SPR is built into the workflow. The sampling robot draws from the bioreactor, the instrument quantifies antibody titer straight from the crude sample, and the number is there while the run is still going. No labels, no manual steps, and no waiting.”
“实时过程控制取决于知道罐里实际有什么,而不只是罐边传感器报告了什么,”Nicoya 工程副总裁 Jamie McQuay 说,“传统上获得这个答案意味着取样品、等实验室。在这个平台中,数字 SPR 内建于工作流:取样机器人从反应器取样,仪器直接从粗样品定量抗体滴度,运行还在进行时数值就出来了。无标记、无手工步骤、无等待。”
The results show that closed-loop glucose control doesn't have to wait for slow, manual lab samples or spectroscopic probe; teams can start on the vessels and data they have available. This approach enables process development teams to rapidly screen multiple process setpoints, media types, and clones while holding glucose and process conditions stable without human intervention.
结果表明,闭环葡萄糖控制不必再等缓慢的人工实验室取样或光谱探头——团队可以直接在现有的罐体和数据上起步。该方法使工艺开发团队能够在无人干预、保持葡萄糖与工艺条件稳定的同时,快速筛选多个工艺设定点、培养基类型与细胞克隆。
图注:手动补料 vs 闭环控制(MPC)的葡萄糖曲线对比:闭环组维持在目标带(4-6 g/L)内,手动组出现过冲与跌破下限。图源:cdn.prod.website-files.com(Basetwo Applied Research Labs)
四方分工(据新闻稿 About 部分)
· Basetwo AI(多伦多):面向制药与先进材料制造企业的智能体 AI 平台,供工艺团队快速构建数字孪生以加速开发、放大与技术转移,并在商业化规模上实时监测与控制质量。
· CPI(英国 High Value Manufacturing Catapult 成员):生物制品方向由其 RNA 卓越中心与药品制造创新中心承接。
· Labman(英国):定制自动化工程公司,开发把生物反应器样品旅程全自动化的平台(分样、样品制备到设备对接),对工作流保持中性。
· Nicoya:生物传感器公司,Alto 数字 SPR 平台提供无标记、实时生物分子分析,直接从粗样品定量抗体滴度。
资料来源:
GlobeNewswire 新闻稿(Basetwo AI,2026-11-11 09:00 ET):https://www.globenewswire.com/news-release/2026/11/11/3400756/0/en/canada-uk-collaboration-demonstrates-autonomous-bioreactor-control-for-a-her2-breast-cancer-therapeutic.html
Basetwo AI 官网同稿:https://basetwo.ai/announcements/basetwo-demonstrates-bioreactor-closed-loop-control-for-a-breast-cancer-therapeutic
配图一(Labman 反应器平台实拍):news-medical.net 转载,Image credit: Labman;配图二(葡萄糖闭环对比图):Basetwo Applied Research Labs
来源:小南AI实验室 · mp.weixin.qq.com